LENZ LENZ Therapeutics
- 15.730
- +0.330+2.14%
- 15.730
- 0.0000.00%
LENZ Therapeutics News
Checkpoint Therapeutics First Quarter 2024 Earnings: US$0.32 Loss per Share (Vs US$0.89 Loss in 1Q 2023)
Earnings Beat: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Last week, you might have seen that 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) released its first-quarter result to the market. The early response was not positive, with shares down 2.6% to US$25.7
Here's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
Knight Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Investors Don't See Light At End Of Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Tunnel And Push Stock Down 25%
Foghorn Therapeutics Inc. (NASDAQ:FHTX) shares have had a horrible month, losing 25% after a relatively good period beforehand. Instead of being rewarded, shareholders who have already held through
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Axsome Therapeutics, Inc., a biopharmaceutica
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)
Arcturus Therapeutics (NASDAQ:ARCT) Making Significant Strides Towards Growth
Earnings Call Summary | Virios Therapeutics(VIRI.US) Q1 2024 Earnings Conference
The following is a summary of the Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript:Financial Performance:Virios Therapeutics reported a decrease in research and development expenses,
Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript
Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript
Earnings Call Summary | DiaMedica Therapeutics(DMAC.US) Q1 2024 Earnings Conference
The following is a summary of the DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript:Financial Performance:DiaMedica reported total combined cash and investments of $46.5 million as o
Earnings Call Summary | Fate Therapeutics(FATE.US) Q1 2024 Earnings Conference
The following is a summary of the Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript:Financial Performance:Fate Therapeutics reported a Q1 revenue of $1.9 million, primarily from the coll
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q1 2024 Earnings Conference
The following is a summary of the Knight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call Transcript:Financial Performance:Knight Therapeutics reported Q1 2024 revenues of over $85 million, a growth o
Earnings Call Summary | LENZ Therapeutics(LENZ.US) Q1 2024 Earnings Conference
The following is a summary of the LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript:Financial Performance:LENZ Therapeutics ended Q1 2024 with a strong cash balance of approximately $213
Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
We're Interested To See How 4D Molecular Therapeutics (NASDAQ:FDMT) Uses Its Cash Hoard To Grow
4D Molecular Therapeutics First Quarter 2024 Earnings: US$0.66 Loss per Share (Vs US$0.88 Loss in 1Q 2023)
Analysis
Price Target
No Data
